ASCO Plenary Mar 2022 - ASCO Plenary Series: March 2022
Mar 15 - Mar 15, 2022 | AlexandriaVAUS
LARVOL is not affiliated with ASCO Plenary Series: March 2022 and all trademarks, logos, and brand names are property of their respective owners
Condition
Product
MOA
Trial Name/ID
Showing 2 abstracts linked to Trials
Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase III study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations
Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)